Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours.

Oncogene - 13 Oct 2011

Rajan N, Elliott R, Clewes O, Mackay A, Reis-Filho J S, Burn J, Langtry J, Sieber-Blum M, Lord C J, Ashworth A

Abstract excerpt

Individuals with germline mutations in the tumour-suppressor gene CYLD are at high risk of developing disfiguring cutaneous appendageal tumours, the defining tumour being the highly organised cylindroma. Here, we analysed CYLD mutant tumour genomes by array comparative genomic hybridisation and gene expression microarray analysis. CYLD mutant tumours were characterised by an absence of copy-number aberrations...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbazoles
Share to Carcinoma, Adenoid Cystic
Share to Deubiquitinating Enzyme CYLD

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Furans

Share to Primary Cell Culture

Share to Receptor, trkB

Share to Receptor, trkC

Share to Tissue Array Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 21552290
DOI: 10.1038/onc.2011.133
PMCID: PMC3175103

Genes

CYLD
BCL2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours.PMID 21552290Read ↗

Transition from cylindroma to spiradenoma in CYLD-defective tumours is associated with reduced DKK2 expression.Semantic proximity Read ↗

Inherited cylindromas: lessons from a rare tumour.Semantic proximity Read ↗

Overexpression of MYB drives proliferation of CYLD-defective cylindroma cells.Semantic proximity Read ↗

CYLD mutations in familial skin appendage tumoursSemantic proximity Read ↗

Cylindromatosis and the <i>CYLD</i> gene: new lessons on the molecular principles of epithelial growth controlSemantic proximity Read ↗

Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial.Semantic proximity Read ↗

Catalytic domain mutation in CYLD inactivates its enzyme function by structural perturbation and induces cell migration and proliferation.Semantic proximity Read ↗

The cylindromatosis gene product, CYLD, interacts with MIB2 to regulate Notch signallingSemantic proximity Read ↗

Understanding Inherited Cylindromas: Clinical Implications of Gene Discovery.Semantic proximity Read ↗

Genetic Testing in CYLD Cutaneous Syndrome: An UpdateSemantic proximity Read ↗

Phenotype variability in tumor disorders of the skin appendages associated with mutations in the CYLD gene.Semantic proximity Read ↗

The cylindromatosis (CYLD) gene and head and neck tumorigenesisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.